Core Viewpoint - Fosun Pharma's subsidiary, Fuhong Hanlin, has received approval from the National Medical Products Administration for clinical trials of HLX43 in combination with HLX07 and Sruvelizumab for the treatment of advanced solid tumors, with plans to conduct Phase II clinical research in China once conditions are met [1] Group 1: Clinical Development - The approved treatment regimen involves a combination of HLX43, HLX07, and Sruvelizumab, which is currently not available in any similar combination therapy approved globally [1] - The total research and development investment for this treatment plan is approximately 2.66 million yuan, expected to be accumulated by December 2025 [1] Group 2: Market Context - The involved investigational drugs are still in the clinical trial phase, indicating that there are inherent risks associated with drug development [1]